Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial

Verify with FDA CVM →

22 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
22
Deaths Reported
10000.0%
Death Rate

Active Ingredients

Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial

Administration Routes

NasalSubcutaneous

Species Affected

Cattle 22

Most Affected Breeds

Mixed (Cattle) 20
Cattle (other) 1
Holstein-Friesian also known as Holstein 1

Most Reported Reactions

Death 22
Lack of efficacy - NOS 16
Necropsy performed 7
Lack of efficacy (bacteria) - NOS 3
Lack of efficacy (mycoplasma) - NOS 1
Extra dose(s) administered 1
Lack of efficacy (virus) - NOS 1
Anaphylactic-type reaction 1
Death by euthanasia 1
Injection site seroma 1
Injection site abscess 1
Third eyelid protrusion 1

Outcome Breakdown

Died
22 (48.9%)
Outcome Unknown
11 (24.4%)
Ongoing
8 (17.8%)
Euthanized
2 (4.4%)
Recovered with Sequela
1 (2.2%)
Recovered/Normal
1 (2.2%)

Data Summary

Metric Value
Total adverse event reports 22
Reports involving death 22
Case-fatality rate (reported events) 10000.0%
Distinct species in reports 1
Distinct breeds in reports 3
Distinct reactions reported 17
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 22 adverse event reports referencing Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial, including 22 reports in which the animal died — a 10000.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial. Reported administration routes include Nasal, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial reports are Cattle (22 reports), with Cattle accounting for the largest share. Within those species, Mixed (Cattle) (20), Cattle (other) (1), Holstein-Friesian also known as Holstein (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial are Death (22), Lack of efficacy - NOS (16), Necropsy performed (7), Lack of efficacy (bacteria) - NOS (3). Of the 45 reports with a coded outcome, Died is the leading category at 48.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Bovine Parainfluenza Virus 3 (Ts), Rlb103 (Nl-Bk-6);Bovine Respiratory Syncytial.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial